Anchiano Therapeutics
Dedicated to the discovery, development, and commercialization of novel targeted therapies to treat cancer
Dedicated to the discovery, development, and commercialization of novel targeted therapies to treat cancer
Anchiano Therapeutics is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel targeted therapies to treat cancer. Founded in 2004, the company operates in the Biotechnology and Health Care industries and is headquartered in the United States. The most recent investment in Anchiano Therapeutics amounted to $23.00M in Post-IPO Equity, taking place on 13 April 2018. This round of funding was led by Shavit Capital and Clal Biotechnology Industries. Anchiano Therapeutics' dedication to developing targeted cancer therapies has attracted significant investment interest from notable venture capital firms, demonstrating confidence in the potential for impactful advancements in cancer treatment.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $23.00M | 2 |
|
13 Apr 2018 |
| Post-IPO Equity | $6.00M | - | 01 May 2016 | |
| Venture Round | ILS13.00M | 1 | Cybele Holdings | 01 Mar 2010 |
We care about your data, and we'd love to use cookies make your experience better.
